The GTS Group advances towards a definitive biomarker for Dementia with Lewy Bodies
The Genomics and Transcriptomics of Synucleinopathies Group led by Dr Katrin Beyer has moved closer towards finding a definitive biomarker for dementia with Lewy bodies (DLB). Their most recent work has been patented and the latest results have been published in the Journal of Alzheimer's Disease. This is the next step following on from work on new experimental models, biomarkers in blood samples and sleep disorders in dementia patients described earlier this year on this website.